Asia-Pacific Biosurgery Market Outlook, 2031

Market Drivers

• Massive and rapidly expanding surgical volumes across the region: Asia Pacific performs tens of millions of surgical procedures annually, with China alone accounting for 97.68 million inpatient surgical procedures in 2024. India performs an estimated 30 million surgeries annually. Japan recorded 898,643 gastroenterological and abdominal surgical procedures and 151,470 cardiovascular surgical procedures in 2024. South Korea performed 2,054,344 major surgeries in 2024. Australia recorded 12.8 million hospitalisations in 2024–25. The breadth and depth of surgical activity across the region ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room. The continued expansion of surgical capacity, driven by hospital modernization, healthcare infrastructure investment, and growing medical tourism, further reinforces this demand driver.
• Demographic pressures from aging populations and rising chronic disease burden: The aging Asia Pacific population represents the most significant long term demand driver. The region is home to approximately 60% of the world's older people, with about 503 million people aged 65 or over currently living in Asia Pacific. Japan has the highest elderly proportion globally at 29.4% (36.19 million people aged 65 and older). South Korea has officially become a "super aged society" with 20.7% of its population (10.72 million people) aged 65 and older. China has 323.38 million people aged 60 and older (23.0% of the population). India has over 107.98 million people aged 65 and older. Australia has 4.996 million people aged 65 and older. The increasing prevalence of chronic diseases, including cardiovascular disorders, cancer, and orthopedic conditions, is leading to more surgical interventions and driving demand for biosurgical products across the region.
• Rapid healthcare infrastructure expansion and government investment: Asia Pacific is experiencing unprecedented healthcare infrastructure development, with governments across the region investing heavily in hospital construction, medical device manufacturing, and healthcare access programs. China's total health expenditure reached 9.2 trillion yuan (6.8% of GDP) in 2025. India's medical devices industry is projected to reach USD 50.1 billion by 2030 under the National Medical Devices Policy, 2023. Japan's PMD Act was significantly amended on May 14, 2025, introducing major revisions for the first time in six years. South Korea's Digital Medical Products Act became effective in January 2025. These investments provide the financial foundation for sustained surgical activity and biosurgical product utilization across the region.

Market Challenges

• Healthcare spending constraints and infrastructure gaps across emerging markets: Despite significant investment, many Asia Pacific countries face persistent healthcare financing challenges. According to the World Health Organization, most developing Asian countries spend just 2–3% of GDP on health, and in many cases public funding amounts to less than $150 per person annually. Hospital bed density varies widely across the region, from India's 1 bed per 1,000 population to Japan's 8,060 hospitals. These financial and infrastructure constraints create pricing pressure on biosurgical products and may limit adoption of premium priced advanced biologics in public healthcare sectors.
• Regulatory fragmentation and varying compliance standards: The Asia Pacific region's diverse regulatory landscape creates significant compliance burdens for manufacturers. Each country maintains distinct regulatory requirements, from Japan's PMDA and China's NMPA to India's CDSCO and Southeast Asian national authorities. Navigating these varying requirements increases time to market and compliance costs, particularly for smaller manufacturers. While regulatory modernization is underway in many countries, harmonization remains limited.
• Healthcare workforce constraints and surgical capacity limitations: Despite rapid healthcare expansion, the region faces significant workforce challenges that could impact surgical capacity. India requires approximately 291,824 additional surgeons by 2030 to meet demand. South Korea experienced a 4.7% decrease in practicing physicians in 2024. These workforce constraints may limit surgical volume growth and, consequently, biosurgical product demand in certain markets.

Market Trends

• Accelerating domestic manufacturing and import substitution: The Asia Pacific biosurgery market is experiencing significant transformation driven by government policies promoting domestic manufacturing. China's NMPA registered 3,400 medical device names in 2025, with approximately 40% developed and produced in China. India's medical devices exports reached USD 4.1 billion in FY25 under the Production Linked Incentive (PLI) Scheme. Japan's PMD Act amendments reinforce quality assurance for domestic manufacturers. Domestic manufacturers are rapidly gaining market share across multiple biosurgery product categories, creating new competitive dynamics.
• Rapid adoption of robotic assisted and minimally invasive surgery: Asia Pacific is witnessing explosive growth in robotic assisted and minimally invasive surgical techniques. China's public hospitals procured 84 robotic surgical systems in 2025. Japan's NCD data shows significant growth in laparoscopic procedures, with 120,625 laparoscopic cholecystectomies in 2024. South Korea's minimally invasive surgery market is expected to grow at a CAGR of 7.9% from 2025 to 2033. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple line reinforcement products compatible with robotic staplers are increasingly in demand.
• Regulatory modernization and digital health integration: Regulatory authorities across the region are modernizing frameworks to facilitate faster market access for innovative medical devices. China's NMPA approved 104 devices to enter the innovative medical device special review process in 2025. South Korea's MFDS published the world's first Guidance on Generative AI Medical Devices in 2025, and the Digital Medical Products Act became effective in January 2025. Japan's PMD Act was significantly amended in May 2025. These regulatory reforms support continued innovation and market entry for advanced biosurgical products.